A Phase 3 interventional study of Aspirin and Tirofiban in Coronary Artery Disease, sponsored by Prince Sultan Cardiac Center, Adult Cardiology Department.. Status unknown at 1 site in Saudi Arabia. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-05-15.
Sponsored by Prince Sultan Cardiac Center, Adult Cardiology Department. · Phase 3, Interventional, and Treatment
This protocol is designed to evaluate the effect of antiplatelets (Tirafiban and Prasugrel) on the incidence of early and intermediate graft patency after CABG.
Coronary artery bypass graft (CABG) surgery is a commonly used revascularization strategy in patients with severe coronary artery disease. Saphenous vein grafts (SVGs) are the most frequently used conduits for this procedure. Unlike arterial grafts, SVGs are particularly susceptible to occlusive thrombosis during the first post-operative year, which exposes patients to increased risks of death, myocardial infarction, and repeat revascularization.
This study is designed to evaluate the effect of antiplatelets (Tirafiban and Prasugrel) on the incidence of early and intermediate graft patency after CABG. Patients will undergo planned cardiac Computed tomographic angiography (CTA) predischarge (at 1 week) and CTA/coronary angiography (CAG) at 6 months to 1 year follow-up. CTA at baseline (predischarge) and follow-up CTA/CAG at 6-12 months after CABG will be used to evaluate graft patency.
5,598 studies on the registry are indexed under Coronary Artery Disease; 957 are open to participants now.
This study's planned enrollment of 200 is above the median of 124 across 3,436 interventional studies indexed under Coronary Artery Disease.
Browse Coronary Artery Disease studies →Prince Sultan Cardiac Center, Adult Cardiology Department. is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Aspirin · Drug: Tirofiban · Drug: Clopidogrel · Drug: Prasugrel
Patient assigned to this arm will receive tirofiban infusion starting approximately six hours post bypass surgery once hemomstasis established and no evidence of bleeding
Drug: Tirofiban · Drug: Clopidogrel · Drug: Prasugrel
Patients receive oral clopidogrel 75 mg 6-8 hours before coronary bypass surgery and continue daily mentenance dose as per instruction by investigators
Drug: Tirofiban · Drug: Clopidogrel · Drug: Prasugrel
Patients started on prasugrel 6 hours post surgery 10 mg then continue on daily 10mg as per instruction by investigators
Drug: Tirofiban · Drug: Clopidogrel · Drug: Prasugrel
Patients continue their maintenance dose not inturrupted by surgery , 81 mg daily
Tirofiban infusion as specified by investigators to start after hemostasis been established
75 mg orally started 6-8hours before surgery
10 mg daily as per instructions of investigators
Venous graft patency
Venous graft patency as assessed by computed tomographic angiography or coronary angiography
Time frame: At one year
Major cardiac events (MACE)
Acute myocardial infarction (AMI), Stroke, minor bleeding, death, rate of revascularization
Time frame: At one year
This study is status unknown, as verified in May 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Prince Sultan Cardiac Center, Adult Cardiology Department.